<DOC>
	<DOC>NCT00150605</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of SPD417 when given with other psychotropic medications to treat bipolar I disorder.</brief_summary>
	<brief_title>Safety of SPD417 Combined With Other Psychotropic Medications in the Treatment of Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Psychotropic Drugs</mesh_term>
	<criteria>DSMIV criteria for Bipolar I disorder Screening YMRS score =&gt;16 Women of childbearing potential agree to take adequate precautions against contraception Currently receiving treatment with antipsychotic therapy or combination therapy of mood stabilizer and antipsychotic Hospitalization required for treatment of psychiatric symptoms Patients who meet DSMIV for ultrarapid cycling History of serious suicide attempt requiring medical intervention Female subjects who are pregnant or lactating, including females with a positive pregnancy test at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
</DOC>